The effect of encasings on quality of life in adult house dust mite allergic patients with rhinitis, asthma and/or atopic dermatitis

AbstractBackground:Sublingual immunotherapy in patients with allergic rhinitis sensitised to house dust mites is safe, but its efficacy is controversial and sublingual immunotherapy withBlomia tropicalishas not yet been studied. This study sought to evaluate the efficacy of sublingual immunotherapy with house dust mite extract in children and adults with house dust mite allergic rhinitis over a period of two years.Methods:A prospective observational study was conducted of children and adults diagnosed with house dust mite allergic rhinitis who were treated with sublingual immunotherapy from 2008 to 2012. Total Nasal Symptom Scores, Mini Rhinoconjunctivitis Quality of Life scores and medication usage scores were assessed prospectively.Results:Thirty-nine patients, comprising 24 children and 15 adults, were studied. Total Nasal Symptom Scores and Mini Rhinoconjunctivitis Quality of Life scores dropped significantly at three months into therapy, and continued to improve. Medication usage scores improved at one year into immunotherapy.Conclusion:Sublingual immunotherapy with house dust mite extracts, includingB tropicalis, is efficacious as a treatment for patients with house dust mite allergic rhinitis.

Download Full-text

Comparison of a generic and a rhinitis-specific quality-of-life (QOL) instrument in patients with house dust mite allergy: relationship between the SF-36 and Rhinitis QOL Questionnaire

Clinical & Experimental Allergy ◽

10.1111/j.1365-2222.2004.02096.x ◽

2004 ◽

Vol 34 (11) ◽

pp. 1673-1677 ◽

Cited By ~ 11

Author(s):

I. Terreehorst ◽

H. J. Duivenvoorden ◽

Z. Tempels-Pavlica ◽

A. J. Oosting ◽

J. G. R. de Monchy ◽

...

Keyword(s):

Quality Of Life ◽

House Dust ◽

House Dust Mite ◽

House Dust Mite Allergy ◽

Mite Allergy ◽

Sf 36 ◽

Dust Mite

Download Full-text

Clinical effectiveness of house dust mite immunotherapy in mono- versus poly-sensitised patients with allergic rhinitis: a systematic review and meta-analysis

Rhinology Journal ◽

10.4193/rhin20.588 ◽

2021 ◽

Vol 0 (0) ◽

pp. 0-0

Author(s):

J.Y. Kim ◽

D. Hwang ◽

M. Jang ◽

C.S. Rhee ◽

D.H. Han

Keyword(s):

Quality Of Life ◽

Systematic Review ◽

Allergic Rhinitis ◽

House Dust ◽

House Dust Mite ◽

Meta Analysis ◽

Clinical Effectiveness ◽

Nasal Symptom ◽

Dust Mite

Selecting an appropriate allergen-specific immunotherapy (AIT) regimen for polysensitised allergic rhinitis (AR) patients is challenging for clinicians. Although previous studies showed comparable effectiveness of single-allergen AIT with house dust mite (HDM) extract between monosensitised and polysensitised AR patients, there is no systematic review and meta-analysis demonstrating the comparable effectiveness of HDM AIT. In this meta-analysis, we analysed nine studies to compare the clinical effectiveness of HDM AIT. The primary outcome was nasal symptom score and secondary outcomes were medication and quality of life scores. The changes in nasal symptom score after HDM AIT did not significantly differ between monosensitised and polysensitised patients. The clinical effectiveness of HDM AIT regarding medication and quality of life score was not significantly different between monosensitised and polysensitised patients). In conclusion, single-allergen AIT with HDM extract showed comparable clinical effectiveness between polysensitised and monosensitised patients with AR.

Download Full-text

Role of IL-22 in Persistent Allergic Airway Diseases Caused by House Dust Mite: A Pilot Study

10.21203/rs.3.rs-47464/v1 ◽

2020 ◽

Author(s):

Laura Tamasauskiene ◽

Vilte Marija Gintauskiene ◽

Daina Bastyte ◽

Brigita Sitkauskiene

Keyword(s):

Quality Of Life ◽

House Dust ◽

House Dust Mite ◽

Nasal Lavage ◽

Control Group ◽

Airway Diseases ◽

Persistent Allergic Rhinitis ◽

Dust Mite ◽

Anti Inflammatory

Abstract Background. Persistent allergic airway diseases cause a great burden worldwide. Their pathogenesis is not clear enough. There is evidence that one of the recently described cytokine interleukin (IL) 22 may be involved in the pathogenesis of these diseases. Scientists argue if this cytokine acts as proinflammatory or anti-inflammatory agent. The aim of this study was to investigate IL-22 level in patients with persistent allergic airway diseases caused by house dust mite (HDM) in comparison with healthy individuals and to evaluate its relationship with IL-13 and IL-10 level, symptoms score and quality of life.Methods. Patients with persistent allergic rhinitis caused by HDM and having symptoms for at least 2 years with or without allergic asthma were involved into the study. Measurements of IL-22, IL-13 and IL-10 and in serum and nasal lavage was performed by ELISA. Questionnaires assessing symptoms severity and quality of life were used.Results. A tendency was observed that IL-22 in serum and nasal lavage was higher in patients with allergic airway diseases compared to control group (14.86 pg/ml vs. 7.04 pg/ml and 2.67 pg/ml vs. 1.28 pg/ml, respectively). Positive statistically significant correlation was estimated between serum IL-22 and serum IL-10 (rs=0.57, p<0.01) and IL-13 (rs=0.44, p<0.05) level. Moreover, positive significant correlation was found between IL-22 in nasal lavage and IL-10 in nasal lavage (rs=0.37, p<0.05). There was a negative statistically significant correlation between serum IL-22 and RQLQ (rs=-0.42, p<0.05).Conclusion. Our study showed a possible anti-inflammatory effect of IL-22 in patients with persistent allergic airway diseases caused by HDM.

Download Full-text

Effect on quality of life of the mixed house dust mite/weed pollen extract immunotherapy

Asia Pacific Allergy ◽

10.5415/apallergy.2016.6.3.168 ◽

2016 ◽

Vol 6 (3) ◽

pp. 168 ◽

Cited By ~ 6

Author(s):

Lisha Li ◽

Kai Guan

Keyword(s):

Quality Of Life ◽

House Dust ◽

House Dust Mite ◽

Pollen Extract ◽

Dust Mite

Download Full-text

The impact of moderate and severe asthma exacerbations on quality of life: a post hoc analysis of randomised controlled trial data

Journal of Patient-Reported Outcomes ◽

10.1186/s41687-020-00274-x ◽

2021 ◽

Vol 5 (1) ◽

Author(s):

Andrew Briggs ◽

Shuaib Nasser ◽

Eva Hammerby ◽

Sarah Buchs ◽

J. Christian Virchow

Keyword(s):

Quality Of Life ◽

Lung Function ◽

House Dust ◽

House Dust Mite ◽

Severe Exacerbation ◽

Health States ◽

Dust Mite ◽

Post Hoc ◽

The Impact

Abstract Background This paper reports the duration of moderate and severe exacerbations in patients with house dust mite induced allergic asthma and the impact on patients’ quality of life. Methods Post-hoc analyses were conducted using data collected during a phase III multi-national trial (MT-04) that investigated time to moderate or severe asthma exacerbation among 485 patients during withdrawal from inhaled corticosteroids. Patient diaries were analysed to ascertain duration of exacerbations. The impact on patients’ quality of life was measured by calculating utilities for five health states using the EuroQol-5 Dimension (EQ-5D-3L) and Asthma Quality of Life Questionnaire (AQL-5D). A regression analysis predicted the disutility of moving from ‘well controlled asthma’ to the other four health states: ‘partially controlled asthma’, ‘uncontrolled asthma’, ‘moderate exacerbation’ and ‘severe exacerbation’. Results Two hundred four patients experienced exacerbations. Moderate and severe exacerbations involved statistically significant reductions in lung function compared to the constant peak expiratory flow observed for patients without exacerbations. Lung function decline occurred for 28 days, decreasing approximately 14 days before an exacerbation followed by a return to baseline over 14 days. Asthma symptoms, the use of short-acting β2-agonists, and frequency of nocturnal awakening all increased, starting 10–14 days before an exacerbation, and returned to baseline within 10–28 days following exacerbations. Compared to ‘well controlled asthma’, the disutility of having a ‘moderate exacerbation’ ranged from − 0.0834 to − 0.0921 (EQ-5D-3L) and from − 0.114 to − 0.121 (AQL-5D); and of having a ‘severe exacerbation’ from − 0.115 to − 0.163 (EQ-5D-3L) and from − 0.153 to − 0.217 (AQL-5D), depending on the length of the observation period. Conclusions The impact of moderate and severe exacerbations in house dust mite induced allergic asthma extends 14 days before and 28 days after the peak exacerbation event. The impact of exacerbations on patients’ health-related quality of life (HRQoL) continues long after their occurrence.

Download Full-text